



Attorney Docket hand been presented to the second of the s Application Number Not yet assigned Filing Date January 19, 2005 INFORMATION DISCLOSURE STATEMENT First Named Inventor BY APPLICANT Lu Art Unit Not yet assigned Not yet assigned **Examiner Name U.S. PATENT DOCUMENTS** Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date. Examiner's Cite No. **Publication Date** Name of Applicant or Patentee Number Initials* (optional) FOREIGN PATENT DOCUMENTS Name of Examiner's Cite No. **Publication Date** Country Number Initials* (optional) Applicant or Patentee Examiner's Cite No. OTHER DOCUMENTS -(optional) Initials* Database NCBI 'Online!' Accession No. NP 006654 (2003). Database NCBI 'Online!' Accession No. NP_505955 (2003). Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved From Worm to Human," Nature Genet. 33:162-167 (2003). Iwabuchi et al., "Stimulation of p53-Mediated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2," J. Biol. Chem. 273:26061-26068 (1998). Naumovski and Cleary, "The p53-Binding Protein 53BP2 Also Interacts with Bcl2 and Impedes Cell Cycle Progression at G₂/M," Mol. Cell. Biol. 16:3884-3892 (1996). Samuels-Lev et al., "ASPP Proteins Specifically Stimulate the Apoptotic Function of

EXAMINER SIGNATURE: DATE CONSIDERED: 4/23/07	
--	--

Slee and Lu, "The ASPP Family: Deciding Between Life and Death After DNA

Immunodeficiency Virus Type 1 by Inhibiting NF-xB and Sp1 Actions," J. Virol.

Takada et al., "RelA-Associated Inhibitor Blocks Transcription of Human

p53," Mol. Cell 8:781-794 (2001).

76:8019-8030 (2002).

Damage," Toxicol. Lett. 139:81-87 (2003).

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.